HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism

Olivier Manches, David H Munn, Anahita Fallahi, Jeffrey Lifson, Laurence Chaperot, Joel Plumas, Nina Bhardwaj

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Plasmacytoid DCs (pDCs) have been implicated as crucial cells in antiviral immune responses. On recognizing HIV, they become activated, secreting large amounts of IFN-α and inflammatory cytokines, thereby potentiating innate and adaptive antiviral immune responses. Here, we have shown that HIV-stimulated human pDCs can also induce the differentiation of naive CD4+ T cells into Tregs with suppressive function. This differentiation was independent of pDC production of IFN-α and primarily dependent on pDC expression of indoleamine 2,3-dioxygenase, which was induced through the TLR/MyD88 pathway, following binding of HIV to CD4 and triggering of TLR7 by HIV genomic RNA. Functionally, the Tregs induced by pDCs were shown to inhibit the maturation of bystander conventional DCs. This study therefore reveals what we believe to be a novel mechanism by which pDC may regulate and potentially limit anti-HIV immune responses.

Original languageEnglish (US)
Pages (from-to)3431-3439
Number of pages9
JournalJournal of Clinical Investigation
Volume118
Issue number10
DOIs
StatePublished - Oct 1 2008

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
HIV
Antiviral Agents
Adaptive Immunity
RNA
Cytokines
T-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. / Manches, Olivier; Munn, David H; Fallahi, Anahita; Lifson, Jeffrey; Chaperot, Laurence; Plumas, Joel; Bhardwaj, Nina.

In: Journal of Clinical Investigation, Vol. 118, No. 10, 01.10.2008, p. 3431-3439.

Research output: Contribution to journalArticle

Manches, Olivier ; Munn, David H ; Fallahi, Anahita ; Lifson, Jeffrey ; Chaperot, Laurence ; Plumas, Joel ; Bhardwaj, Nina. / HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. In: Journal of Clinical Investigation. 2008 ; Vol. 118, No. 10. pp. 3431-3439.
@article{28af7f194bd84dcf97494194936095cd,
title = "HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism",
abstract = "Plasmacytoid DCs (pDCs) have been implicated as crucial cells in antiviral immune responses. On recognizing HIV, they become activated, secreting large amounts of IFN-α and inflammatory cytokines, thereby potentiating innate and adaptive antiviral immune responses. Here, we have shown that HIV-stimulated human pDCs can also induce the differentiation of naive CD4+ T cells into Tregs with suppressive function. This differentiation was independent of pDC production of IFN-α and primarily dependent on pDC expression of indoleamine 2,3-dioxygenase, which was induced through the TLR/MyD88 pathway, following binding of HIV to CD4 and triggering of TLR7 by HIV genomic RNA. Functionally, the Tregs induced by pDCs were shown to inhibit the maturation of bystander conventional DCs. This study therefore reveals what we believe to be a novel mechanism by which pDC may regulate and potentially limit anti-HIV immune responses.",
author = "Olivier Manches and Munn, {David H} and Anahita Fallahi and Jeffrey Lifson and Laurence Chaperot and Joel Plumas and Nina Bhardwaj",
year = "2008",
month = "10",
day = "1",
doi = "10.1172/JCI34823",
language = "English (US)",
volume = "118",
pages = "3431--3439",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "10",

}

TY - JOUR

T1 - HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism

AU - Manches, Olivier

AU - Munn, David H

AU - Fallahi, Anahita

AU - Lifson, Jeffrey

AU - Chaperot, Laurence

AU - Plumas, Joel

AU - Bhardwaj, Nina

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Plasmacytoid DCs (pDCs) have been implicated as crucial cells in antiviral immune responses. On recognizing HIV, they become activated, secreting large amounts of IFN-α and inflammatory cytokines, thereby potentiating innate and adaptive antiviral immune responses. Here, we have shown that HIV-stimulated human pDCs can also induce the differentiation of naive CD4+ T cells into Tregs with suppressive function. This differentiation was independent of pDC production of IFN-α and primarily dependent on pDC expression of indoleamine 2,3-dioxygenase, which was induced through the TLR/MyD88 pathway, following binding of HIV to CD4 and triggering of TLR7 by HIV genomic RNA. Functionally, the Tregs induced by pDCs were shown to inhibit the maturation of bystander conventional DCs. This study therefore reveals what we believe to be a novel mechanism by which pDC may regulate and potentially limit anti-HIV immune responses.

AB - Plasmacytoid DCs (pDCs) have been implicated as crucial cells in antiviral immune responses. On recognizing HIV, they become activated, secreting large amounts of IFN-α and inflammatory cytokines, thereby potentiating innate and adaptive antiviral immune responses. Here, we have shown that HIV-stimulated human pDCs can also induce the differentiation of naive CD4+ T cells into Tregs with suppressive function. This differentiation was independent of pDC production of IFN-α and primarily dependent on pDC expression of indoleamine 2,3-dioxygenase, which was induced through the TLR/MyD88 pathway, following binding of HIV to CD4 and triggering of TLR7 by HIV genomic RNA. Functionally, the Tregs induced by pDCs were shown to inhibit the maturation of bystander conventional DCs. This study therefore reveals what we believe to be a novel mechanism by which pDC may regulate and potentially limit anti-HIV immune responses.

UR - http://www.scopus.com/inward/record.url?scp=55849140547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55849140547&partnerID=8YFLogxK

U2 - 10.1172/JCI34823

DO - 10.1172/JCI34823

M3 - Article

VL - 118

SP - 3431

EP - 3439

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 10

ER -